Neena Brizmohun
Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Latest From Neena Brizmohun
First Academic Sponsor On EMA’s PRIME Pledges Cheaper CAR-Ts
An investigational CAR T-cell therapy that hospital researchers in Spain believe they could produce at a third of the price of commercially available CART19 products has been accepted onto the European Medicines Agency's priority medicines scheme.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add one new product – Lumykras, Amgen’s treatment for advanced non-small cell lung cancer.
Lynparza Rejection Highlights ‘Two-Tier’ Funding Problem In UK
Health technology assessment body NICE has said that Lynparza from AstraZeneca and MSD is not a cost-effective use of National Health Service resources in England for prostate cancer patients at the price at which it is currently being offered. AZ and NICE say they will try to reach an agreement.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add seven new products, including Janssen-Cilag’s Rybrevant for treating patients with advanced non-small cell lung cancer.
New EU Filings
Infigratinib, Helsinn Group’s treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
Search Over For New Chief For England’s NICE
NICE, which is seen as a global leader when it comes to assessing the clinical and cost effectiveness of health care products, has appointed Samantha Roberts as its third chief executive in its over 20-year history.